Takeda Pharmaceutical (NYSE:TAK) Rating Lowered to “Strong Sell” at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on TAK. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Takeda Pharmaceutical currently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.2%

Shares of TAK stock opened at $16.02 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. The company has a market cap of $50.97 billion, a price-to-earnings ratio of 41.07 and a beta of -0.08. The stock’s fifty day moving average price is $16.13 and its 200 day moving average price is $16.83. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. On average, research analysts expect that Takeda Pharmaceutical will post 0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership raised its stake in shares of Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the last quarter. UBS Group AG boosted its stake in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of Takeda Pharmaceutical by 407.9% in the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical by 98.4% during the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after acquiring an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC grew its holdings in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after acquiring an additional 880,289 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.